Next-Generation Techniques for Discovering Human Monoclonal Antibodies


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term next-generation antibody-discovery platforms has already been established in the literature to refer to these approaches. Our review focuses on describing the results obtained by these methods.

Sobre autores

A. Lushova

Institute of Immunology

Email: avfilat@yandex.ru
Rússia, Moscow, 115478

M. Biazrova

Institute of Immunology

Email: avfilat@yandex.ru
Rússia, Moscow, 115478

A. Prilipov

Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology

Email: avfilat@yandex.ru
Rússia, Moscow, 123098

G. Sadykova

Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology

Email: avfilat@yandex.ru
Rússia, Moscow, 123098

T. Kopylov

Orekhovich Institute of Biomedical Chemistry

Email: avfilat@yandex.ru
Rússia, Moscow, 119121

A. Filatov

Institute of Immunology

Autor responsável pela correspondência
Email: avfilat@yandex.ru
Rússia, Moscow, 115478

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Inc., 2017